You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A2a Adenosine Agonists for Diabetic Nephropathy

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Diabetic nephropathy (DN) accounts for approximately 40% of the cases of renal failure requiring dialysis or transplantation. Moreover, diabetic nephropathy is associated with markedly higher morbidity and mortality rates. It is important to develop novel interventions to prevent complications of diabetes. Inflammation in the genesis of diabetes, as well as its ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  2. A2a Adenosine Blockers for Parkinson's Disease

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (PROVIDED BY APPLICANT): Selective antagonists of A2A adenosine receptors have proven to be effective for the treatment of Parkinson's disease (PD) both in animal models and in a human trial. However, the initial clinical trial was stopped in phase 3 due to detection of animal toxicity of KW6002. Other investigational compounds lack sufficient potency, selectivity or bioavailability to ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  3. Genetic Assay for Inhibitors of RNA-Protein Interactions

    SBC: ADVANCED GENETIC SYSTEMS, INC.            Topic: N/A

    RNA-protein interactions play critical roles in cellular regulatory processes and in the life cycles of many pathogenic viruses including HIV, hepatitis C, SARS, and West Nile virus, and thus represent attractive targets for therapeutics. We have developed novel cell-based assays to identify drugs that target the RNA-protein interactions. The assays incorporate a system of genetic reporters to acc ...

    STTR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  4. High Resolution Digital Imaging X-ray Detectors

    SBC: Aguila Technologies, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The aim is to develop a high resolution, high contrast detector for digital x-ray imaging systems. The target detector would have a Detective Quantum Efficiency much greater than 80%, a limiting resolution of at least 10 lp/mm, ultra-low noise, linear response and a dynamic range of more than 14 bits. The proposal is to build such a detector by using CdZnTe c ...

    STTR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  5. Histone Deacetylase Inhibitors for Cancer Treatment

    SBC: Angiogen, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Histone deacetylases (HDACs) comprise a family of enzymes that catalyze the removal of acetyl groups from lysine residues of histones. They mediate chromatin remodeling and gene expression. HDAC inhibitors are potent inducers of growth arrest, differentiation or apoptic cell death and suppress cell proliferation in a variety of transformed cells in culture and ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  6. Amino acid derived urea based chemicals as sEH inhibitor

    SBC: Arete Therapeutics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Recent findings indicate that increasing levels of epoxides of arachidonic acid (EETs) appear to be new and excellent means to treat both hypertension and vascular inflammation. We demonstrated that in vivo inhibition of soluble epoxide hydrolase resulted in higher levels of EETs and in reduction of blood pressure and inflammation in animal models. Because the ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  7. Novel epoxide hydrolase inhibitor for stroke prevention

    SBC: Arete Therapeutics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): A major cause of morbidity and mortality is the progression of organ damage associated with cardiovascular diseases. For instance, the incidence of stroke and costs associated with stroke damage continues to have a devastating impact on public health despite numerous treatments aimed at cardiovascular risk factors. Recent findings indicate that increasing lev ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  8. Quantitation Pulmonary Delivery of Therapeutic Protein

    SBC: Arizeke Pharmaceuticals, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Arizeke Pharmaceuticals, Inc. is focused on the pulmonary delivery of protein therapeutics (including antibodies) to treat pulmonary disease. Arizeke's technology provides a unique ability to deliver large therapeutic proteins into the lung parenchyma and interstitium and into the lymphatic drainage system. Examples of indications that can be targeted by this t ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  9. Radiosensitization by modulating inhibitors of apoptosis

    SBC: Ascenta Therapeutics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Radioresistance markedly impairs the efficacy of tumor radiotherapy and involves anti-apoptotic signal transduction pathways that prevent radiation-induced cell death. The inhibitors of apoptosis proteins (IAP) are important intrinsic cellular inhibitors of apoptosis, highly expressed in prostate and lung cancer cells, and play an important role in resistance ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  10. AEGIS: A Pixel-array Readout IC for Gamma-ray Imaging

    SBC: Augustine Engineering            Topic: N/A

    DESCRIPTION (provided by applicant): CdZnTe arrays are promising detectors for improving nuclear medicine imaging, but existing CdZnTe cameras have limited spatial resolution and small numbers of pixels (space bandwidth product = SpBW). We show that major performance improvements will require high SpBW (>10A5) and small pixels (high resolution). The best approach to obtaining high SpBW detectors i ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government